Chapter 987 Joint Venture

"In this cooperation with Russia, Russian oil giants including Lukoil require that the long-term sales agreement signed with us have a flexible adjustment mechanism based on market prices..."

Regarding the words of United Energy Group CEO Epeli Singleton, Barron didn't know what to say for a moment...

After a while, he said calmly:

"Well, that's what we were hoping for, but it's also nice to be able to make them feel like they're in the driver's seat."

Although it is no longer the BFT Fund that is cooperating with the Russian oil giants this time, the "crude oil bet" between the BFT Fund and these Russians impressed them more...

Take Lukoil, for example. Its president, Vagit Alekperov, still has a vivid memory of the profits that the BFT Fund received from Lukoil due to the soaring international crude oil prices - although Lukoil was only in He made less money during that price surge and did not owe anything, but it still made him feel bad.

This is why this time United Energy Group cooperates with Russian oil and gas giants. They require that a mechanism for adjusting oil and gas prices according to market changes must be added...

They are really worried that history will repeat itself again. If the price skyrockets again after the contract is signed this time, it will not be so pleasant.

In fact, they guessed it right, but only half of it, because this year's oil and gas prices will change greatly, but they will not rise, but fall. Oil and gas prices will fall by more than half throughout the year. These declines are mainly concentrated in in the second half of the year.

Of course, this is what happened in the original time and space. Many times, Barron's actions in the investment market will take into account the impact on his industry. Therefore, Barron himself is still hesitant about whether to control or inhibit participation in crude oil this time. Investments that have experienced declines and related declines in commodity prices...

After all, the cooperation with Russia and the scale of purchasing their oil and gas products are not small.

Moreover, United Energy Group and Colo itself have considerable oil and gas exploration. The decline in oil and gas prices will inevitably have a profound impact on these industries.

However, this year's drop in oil and gas prices itself was affected by many factors - the Federal Reserve's withdrawal from quantitative easing, which led to the strengthening of the U.S. dollar, coupled with reduced global demand, led to the drop in oil and gas prices...

And before that, a lot of capital was long on oil and gas prices, and they began to reduce their positions on a large scale in the second half of this year, causing a panic decline...

Barron doesn't think they can fight this trend entirely through the capital market...

In this case, when negotiating with Russian oil and gas giants about the purchase price adjustment mechanism, the other party has become more proactive...

Then DS Group has no psychological burden at all and can prepare to intervene in this wave of sharp declines in oil and gas prices, which in turn will lead to a decline in commodity prices.

As for United Energy Group and Colo Petroleum Company, they will also add corresponding futures short arbitrage based on their oil and gas production.

…

Throughout March, what attracted the most attention to the British people and the global pharmaceutical field was that GlaxoSmithKline, the largest pharmaceutical company in the UK, announced that it had replaced its chairman and CEO.

As Barron's investment in GlaxoSmithKline through its new fund European Wealth Fund has increased since this year, DS Group and its related capital have now cumulatively controlled 25% of GlaxoSmithKline's shares, plus their Influence - Other shareholders of GlaxoSmithKline also maintain close cooperative relations with DS Group.

As a result, they have taken control of GlaxoSmithKline's board of directors and announced in March that its chairman and CEO Andrew Witty will "retire" early. Emma Walmsley, who manages the consumer healthcare business, will succeed Andrew Witty and become the first female head of GlaxoSmithKline.

"My goal is to lead GlaxoSmithKline's transformation. I hope to focus on research and development and bring better products to users..."

I have to say that Emma Walmsley is very determined...

After becoming the leader of GlaxoSmithKline, the first decision she made was to cooperate with Pfizer and merge the consumer health care products businesses of both parties - you know, before that, Emma Walmsley He is the head of GlaxoSmithKline’s consumer healthcare business.

“The merger of the consumer health care products business of both parties will save a lot of costs and occupy the first or second market share in the health care products business in all key regions, including the United States and China. This is a positive development for GlaxoSmithKline. Something that is beneficial to both Pfizer and Pfizer..."

It can be said that this time Emma Walmsley chose Pfizer Pharmaceuticals as a partner in the field of consumer health products, also taking into account the influence of His Royal Highness the Duke, the controlling shareholder of GlaxoSmithKline, in Pfizer Pharmaceuticals.

After all, in addition to controlling 25% of GlaxoSmithKline's shares, Barron also controls more than 20% of Pfizer's shares, which is the driving force behind the cooperation between the two parties.

According to the negotiation between the two parties, after the merger of the two businesses, the name of the joint venture will be GSK Consumer Healthcare, of which GSK owns 68% of its shares and Pfizer owns 32% of the shares - this integration involves multiple products of both parties, such as Sensodyne, Fenbid, Centrum, etc.

The joint venture will focus on the integration of the business, and it is expected that by 2015, the two businesses will save 500 million pounds a year. At the same time, they also stated that up to 25% of the cost savings will be reinvested in the business to support innovation and other growth opportunities.

At the same time, GSK plans to divest the joint venture from the company within three years and list its consumer healthcare business in the UK and the United States.

The error-free version is reading! 6=9+Book_Bar first published this novel.

The management of GSK Consumer Healthcare will also be mainly composed of GSK executives, and Pfizer will have the right to appoint three of the nine members of the joint venture board of directors.

After the announcement of the cooperation between the two parties, the share prices of GlaxoSmithKline and Pfizer both rose slightly, which also shows that the market is still very optimistic about the cooperation between the two parties.

"GSK needs to maintain its strength in R&D, whether it is cancer drugs or vaccine business..."

This is what Barron said when he met Emma Walmsley last time.

At that time, Emma Walmsley hoped to establish a genome research laboratory within the company, increase investment in tumor drugs, and focus on R&D.

Barron basically agreed with her strategy and specifically reminded that GlaxoSmithKline should not relax in the vaccine business.